Application of GalvoC in preparation of product for resisting skin aging and / or promoting skin repair

Abstract

The invention relates to an application of GalvoC in preparation of a product for resisting skin aging and / or promoting skin repair. A large number of experiments prove that the GalivoC has good safety in preparation of products for resisting skin aging and / or promoting skin repair, and has great clinical application prospects and values, specifically, the GalivoC can activate expression of SIRT1 protein, significantly inhibit activity of matrix metalloproteinase MMP1, and can be used for preparing anti-aging products for skin and / or promoting skin repair, so that the GalivoC can be used for preparing anti-aging products for skin and / or promoting skin repair. The synthesis of collagen type I and collagen type III is promoted, so that the reduction of the content of various collagens in skin keratinocytes caused by UV light aging stimulation is improved, the healing ability of cell scratches is promoted, and the effect is superior to that of the existing activator resveratrol.

Description

Technical Field

[0001] The present application relates to the field of biomedical technology, and in particular to the use of Garsenwo C in the preparation of products for anti-aging and / or promoting skin repair. Background Art

[0002] Skin aging is the result of the combined effects of internal and external factors, manifested in changes in appearance and function. From the perspective of appearance changes, it can be generally seen that wrinkles and fine lines increase, skin sagging, loss of elasticity, dull skin color, increased spots, dry and rough skin, etc. Functional changes are generally manifested in weakened barrier function, susceptibility to irritation, repair ability, slower wound healing, reduced immune function, susceptibility to infection or inflammation, etc.

[0003] There are many microscopic mechanisms that lead to skin aging, including: at the cellular level, telomeres shorten and function weaken after cell division, leading to cell aging; ultraviolet rays induce the generation of free radicals, which damage cell membranes, proteins, and DNA, accelerating cell apoptosis; matrix metalloproteinases decompose collagen, leading to collagen loss and accelerating skin aging, etc. Summary of the invention

[0004] Based on this, the purpose of this application includes providing the use of Jiashengwo C in the preparation of products for skin anti-aging and / or promoting skin repair.

[0005] The technical solution of this application is as follows:

[0006] The present invention provides the use of Garsengwo C in preparing products for anti-aging and / or promoting skin repair.

[0007] In one embodiment, the product further comprises auxiliary materials.

[0008] In one embodiment, the administration of the product includes oral administration and / or topical administration.

[0009] In one embodiment, the product includes cosmetics, food or medicine.

[0010] In one embodiment, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

[0011] In one embodiment, the food comprises one or more of functional food, beverage, health product and nutritional supplement.

[0012] In one embodiment, the dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

[0013] In one embodiment, the external application includes local transdermal administration and / or systemic transdermal administration.

[0014] In one embodiment, anti-aging and / or promoting skin repair refers to activating the expression of SIRT1; and / or

[0015] Skin anti-aging and / or skin repair promotion refers to inhibiting the activity of matrix metalloproteinases; and / or

[0016] Skin anti-aging and / or skin repair promotion refers to promoting collagen expression; and / or

[0017] Skin anti-aging and / or skin repair refers to promoting cellular healing.

[0018] In one embodiment, the matrix metalloproteinase is MMP1; the collagen is one or both of type I collagen and type III collagen.

[0019] Compared with the prior art, this application has the following beneficial effects:

[0020] The inventors of this application have confirmed through a large number of experiments that Garsenwo C has good safety in the preparation of products for anti-aging and / or promoting skin repair, and has great clinical application prospects and value. Specifically, Garsenwo C can activate the expression of SIRT1 protein, significantly inhibit the activity of matrix metalloproteinase MMP1, promote the synthesis of collagen Ⅰ and Collagen Ⅲ, and thus improve the decrease in the content of various collagens in skin keratinocytes caused by UV photoaging stimulation, promote the healing ability of cell scratches, and the effect is better than the existing activator resveratrol. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0022] Figure 1 This is a graph showing the toxicity test results of Gashengwo C on immortalized keratinocytes of human skin in Example 1.

[0023] Figure 2 This is a diagram showing the activation effect of Garsengwo C on SIRT1 protein in Example 1.

[0024] Figure 3 This is a graph showing the inhibitory effect of Gashengwo C on matrix metalloproteinase MMP1 in Example 1.

[0025] Figure 4 This is a diagram showing the promoting effect of Garsenwo C on the expression of various collagens in Example 1.

[0026] Figure 5 This is a diagram showing the healing-promoting effect of Gastrointestinal Pathology C on human skin immortalized keratinocytes after scratching in Example 1. DETAILED DESCRIPTION

[0027] In order to make the above-mentioned purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are described in detail below. In the following description, many specific details are set forth to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present application, so the present application is not limited by the specific embodiments disclosed below.

[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0029] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0030] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0031] Herein, "pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound in the structure shown and an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present application and an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by the compound of the present application and a base. Suitable bases for forming salts include but are not limited to alkali metal salts (such as sodium salts or potassium salts), alkaline earth metal salts (such as magnesium salts or calcium salts), ammonium salts (such as lower alkanolammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0032] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc. Rice oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffered saline; (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0033] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.

[0034] Herein, the optional scope of "and / or", "or / and", and "and / or" includes any one of two or more related listed items, and also includes any and all combinations of related listed items, and the said any and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0035] Herein, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0036] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values ​​of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.

[0037] Only some numerical ranges are specifically disclosed herein. However, any lower limit can be combined with any upper limit to form an undefined range; and any lower limit can be combined with other lower limits to form an undefined range, and any upper limit can be combined with any other upper limit to form an undefined range. In addition, each separately disclosed point or single value itself can be combined with any other point or single value as a lower limit or upper limit or with other lower limits or upper limits to form an undefined range. The use of numerical ranges represented by endpoints includes all numbers within the range and any range within the range, for example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 2, 2.75, 3, 3.80, 4 and 5, etc.

[0038] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.

[0039] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0040] The temperature parameters in this application, unless otherwise specified, allow both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±2°C, ±1°C, ±0.5°C, ±0.4°C, ±0.3°C, ±0.2°C, and ±0.1°C are allowed. Normal temperature or room temperature in this application refers to no temperature control operation, generally 4°C~35°C, preferably 20±5°C.

[0041] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0042] Silent information regulator 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD + ) and belongs to the Sirtuin protein family. It plays an important role in regulating cell metabolism, anti-oxidation, anti-aging and maintaining genome stability. SIRT1 regulates the activity of multiple target proteins by removing acetyl groups from proteins, affecting cell metabolism, stress response and gene expression. SIRT1 achieves antioxidant effects by activating antioxidant pathways (such as FOXO transcription factors) and reducing the damage of free radicals to cells. It can also delay cell aging by regulating telomere length, DNA repair and cell apoptosis; SIRT1 participates in the DNA repair process, reduces gene mutations and chromosomal abnormalities and maintains genome stability. SIRT1 is a hot target in anti-aging research. By activating SIRT1, aging can be delayed, metabolism can be improved and diseases can be prevented. It is an important target for anti-aging and disease treatment research.

[0043] Garcinone C is a xanthone derivative with the chemical formula C 23 H 26 O7, the structural formula is as follows: . Garcinone C is a natural compound extracted from Garcinia oblongifolia, which can be used as an anti-inflammatory, astringent and granulation-promoting active molecule with potential cytotoxic effects on certain cancers. Studies have shown that Garcinone C can stimulate the expression levels of ATR and 4E-BP1, while effectively inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, CDC2, STAT3 and CDK7. Garcinone C significantly inhibited the cell viability of human nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time- and dose-dependent manner.

[0044] Studies have shown that Garcinone C has significant antioxidant capacity, can scavenge free radicals, and reduce the damage of oxidative stress to cells; it can also reduce inflammatory responses by inhibiting the expression of inflammatory mediators (such as NF-κB and COX-2); Garcinone C activates the caspase pathway and regulates Bcl-2 family proteins, induces cell apoptosis, inhibits cell proliferation and blocks the cell cycle to achieve anti-tumor effects; Garcinone C has multiple biological activities and has high application value in anti-oxidation, anti-inflammatory, anti-tumor and anti-viral aspects. The antioxidant and anti-inflammatory properties of Garcinone C make it a potential ingredient for anti-aging and skin care products. However, no studies have shown that Garcinone C can affect the expression of the aging-related protein SIRT1, and its function in skin protection.

[0045] Based on this, the present invention provides the use of Jiashengwo C in the preparation of skin anti-aging and repair products.

[0046] In some of these examples, the product also includes excipients.

[0047] In some examples, the product is administered orally and / or topically.

[0048] In some examples, the external use includes local topical administration and / or systemic transdermal administration.

[0049] In some of these examples, skin anti-aging includes one or more of improving skin photoaging, improving wrinkles, improving pigmentation, and improving skin sagging.

[0050] In some of these examples, skin anti-aging and / or skin repair promotion refers to activating the expression of SIRT1. Specifically, Garsenwo C can be used as a deacetylase SIRT1 activator to increase the activity of SIRT1 protein, and this application has experimentally discovered for the first time that Garsenwo C can activate the expression of SIRT1 protein, and the effect is better than the recognized activator resveratrol.

[0051] In some of these examples, skin anti-aging and / or skin repair promotion refers to inhibiting the activity of matrix metalloproteinases.

[0052] In some of the examples, the matrix metalloproteinase is MMP1. Specifically, the present application first discovered that the compound Garsenwo C can significantly inhibit the activity of matrix metalloproteinases, thereby improving the abnormal increase of MMP1 in skin keratinocytes caused by UV light aging stimulation.

[0053] MMP is the abbreviation of matrix metalloproteinase, which is a family of proteases that depend on zinc and calcium ions. They can degrade various components of the extracellular matrix (ECM), such as collagen, elastin, gelatin, etc., and play an important role in physiological and pathological processes such as tissue remodeling, wound healing, inflammation and cancer.

[0054] The MMP1 (Matrix Metalloproteinase-1) described in this article, also known as collagenase-1, is an enzyme that can degrade extracellular matrix (ECM) components and belongs to the matrix metalloproteinase (MMPs) family. MMP1 mainly degrades type I collagen and type III collagen, which are the main components of the skin's extracellular matrix and are essential for maintaining skin structure and elasticity; therefore, by inhibiting the activity of MMP1, collagen degradation is reduced, thereby delaying skin aging. In the medical field, regulating the activity of MMP1 helps promote wound healing and tissue repair; at the same time, it can help clear damaged tissues and promote the migration of inflammatory cells, which has a certain anti-inflammatory effect.

[0055] In some of these examples, skin anti-aging and / or skin repair promotion refers to promoting collagen expression.

[0056] In some of the examples, the collagen is one or both of type I collagen and type III collagen. Specifically, the present application first experimentally discovered that Gashengwo C can promote the expression of collagen, thereby improving the reduction of collagen content in skin keratinocytes caused by UV light aging stimulation.

[0057] In some of these examples, skin anti-aging and / or skin repair promotion refers to promoting cell healing. Specifically, this application first experimentally discovered that Gashengwo C can promote the healing ability of cell scratches, promote skin wound healing, and accelerate repair.

[0058] In some of these examples, the product includes a cosmetic, a food, or a medicine.

[0059] In some of the examples, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

[0060] In some examples, the food includes one or more of functional food, beverage, health product and nutritional supplement.

[0061] In some examples, the drug includes the active ingredient, Glucosamine C, and pharmaceutically acceptable excipients. Further, the pharmaceutically acceptable excipients include, but are not limited to, pharmaceutically acceptable salts, diluents, wetting agents, adhesives, disintegrants, lubricants, color and flavor regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, local analgesics, pH regulators, isotonic or isotonic regulators, etc.

[0062] In some examples, the dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection. It is understandable that the drug of the present application can be added with different pharmaceutically acceptable excipients to prepare suitable clinical dosage forms, which include but are not limited to the dosage forms described herein.

[0063] In some of these examples, the drug can be administered using a suitable route of administration based on clinical needs. It can be understood that the routes of administration of the drug include intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0064] In summary, the present application discloses a novel application of SIRT1 activator in resisting skin photoaging, wherein the compound is composed of Garsengwo C. The compound has the function of activating the aging-related protein SIRT1, while promoting the expression of various types of collagen in immortalized keratinocytes of human skin, promoting the healing ability of skin cells, and has no obvious side effects, and can be used to prepare applications related to skin anti-aging.

[0065] The following is further described in conjunction with specific embodiments. The raw materials involved in the following specific embodiments, unless otherwise specified, can all be commercially available; the instruments used, unless otherwise specified, can all be commercially available; the processes involved, unless otherwise specified, are all routinely selected by those skilled in the art.

[0066] Some of the raw materials used in the embodiment are as follows:

[0067] Human skin immortalized keratinocytes (HaCaT) were purchased from Zhejiang Meisen Cell Technology Co., Ltd.;

[0068] Resveratrol and Garcinone C were purchased from MedChemExpress.

[0069] The positive control compound used in this paper is resveratrol, a polyphenolic substance also known as stilbene. It is a natural antitoxin produced by various plants when exposed to external stimuli. Its chemical formula is C 14 H 12 O3. Resveratrol has the ability to scavenge free radicals and inhibit their generation. It can also regulate the activity associated with antioxidant enzymes, thereby preventing cell aging caused by lipid peroxides, fundamentally solving the problem of skin damage, delaying skin aging, and achieving an anti-growth effect. In addition, resveratrol can also reduce the formation of melanin by inhibiting the activity of melanocytes and tyrosinase, thereby achieving the effect of whitening the skin. As a potent SIRT1 inducer, resveratrol can activate acetylase and increase the expression of SIRT1 in tissues such as the brain, heart, intestines, kidneys, muscles, and fat. It can also promote the proliferation of collagen, fibroblasts, and epidermal keratinocytes, enhance skin elasticity, and significantly extend life by 50%. Studies have shown that resveratrol not only helps support wound healing and reduce the formation of excessive scars, but also effectively prevents skin aging caused by ultraviolet light.

[0070] The following are specific embodiments.

[0071] Example 1

[0072] 1. Cell culture: Immortalized human skin keratinocytes (HaCaT) were used in the experiment and fully mixed with DMEM complete medium. 5 Inoculate in a 6cm cell culture dish and culture in a cell culture incubator at 37℃, 5% CO2 and saturated humidity. The cells adhere to the wall and grow to cover 80% of the bottom area of ​​the culture dish. When subculturing, aspirate the original culture medium, wash twice with PBS, digest with 0.25% trypsin, and stand in the cell culture incubator for 7 minutes. When the cells shrink and become round and gradually fall off from the culture bottle, add 2 times the volume of trypsin complete culture medium to stop digestion, collect the cell suspension, centrifuge, resuspend with an appropriate amount of complete culture medium, count and transfer a certain concentration of cells to a new culture dish, add 10mL culture medium, mix the cells and evenly spread them in the dish.

[0073] 2. Cell drug treatment: When the cells reach the logarithmic growth phase, they are digested and counted at 6×10 5 / mL cells were seeded in a 6 cm culture dish (5×10 5 in 6-well plate; 1×10 4The cells were placed in a 96-well plate and placed in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 24 hours. After the cells adhered to the wall, the model group and the drug-treated group were exposed to ultraviolet light for 90 minutes using an ultraviolet aging box UVA95%+UVB5% to simulate natural light, and then the culture medium was replaced. The model group was added with an equal amount of complete culture medium, and the drug-treated group was added with complete culture medium of each drug at the corresponding concentration. The cells were then placed in a cell culture incubator and cultured for the required time for subsequent experimental testing. The control group was treated with no ultraviolet irradiation or drug treatment, and the operation was similar to that of the model group after 90 minutes of ultraviolet irradiation, and the drug-free culture medium was replaced simultaneously.

[0074] The drugs used in the drug treatment group include resveratrol solution and Garcinone C solution, and the preparation methods are as follows: resveratrol and Garcinone C are dissolved in dimethyl sulfoxide (DMSO) to prepare 10mM stock solutions, which are then diluted according to their respective working concentrations in the experiment.

[0075] 3. Drug safety test: When the density of drug-treated cells in the 96-well plate reaches about 80% of the bottom area of ​​the culture dish, replace the original drug-treated culture medium according to the ratio of CCK-8 reagent and cell culture medium (1:10), continue to culture in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 2 hours, detect the absorbance at a wavelength of 450nm, calculate the effect of the drug on the survival rate of the cells, and then judge the toxicity of the drug. The results are as follows Figure 1 As shown, the results indicate that Garcinone C has no significant effect on cell viability within the concentration range of 0-3.5 μM, has good safety, and can be regarded as a safe concentration range.

[0076] 4. Detection of the effect of drugs on the expression of aging-related proteins SIRT1, matrix metalloproteinase MMP1 and various types of collagen: After UV stimulation of cell modeling, Garcinone C (1μM) and resveratrol (1μM) were added to the drug treatment group to treat human immortalized keratinocytes for 24h. After that, the cells were collected, proteins were extracted, and used for WB (Western Blot) experiments. This application detects SIRT1, MMP1 and various types of collagen. By comparing with the control group, it can be judged whether the model group is successfully established. If the expression of SIRT1 and collagen in the model group is significantly reduced and MMP1 is significantly increased compared with the control group, the model is successfully established, otherwise it is unsuccessful. At the same time, the drug treatment group compares whether the expression of SIRT1 and collagen in the model group is increased and whether MMP1 is decreased, to determine the activation effect of the drug on SIRT1 and inhibit the expression of matrix metalloproteinase MMP1 and promote collagen expression.

[0077] The results are as follows Figure 2-Figure 4As shown in the figure, the results show that Garcinone C can significantly activate the expression of SIRT1, and has a significant promoting effect on the synthesis of collagen Ⅰ and collagen Ⅲ; at the same time, it has an inhibitory effect on matrix metalloproteinase MMP1. Compared with the resveratrol positive drug control group at the same concentration, the activation effect of SIRT1 is stronger, the promotion effect of collagen expression is stronger, and the inhibition effect of matrix metalloproteinase expression is stronger.

[0078] 5. Detection of the effect of drugs on wound healing ability of cell scratches: Cells were seeded in 6-well plates (5×10 5 / well), cultured into a monolayer. When the cell fusion rate reached 100%, the culture medium was replaced after 90 minutes of ultraviolet irradiation using an ultraviolet aging box UVA95% + UVB5% to simulate natural light. Use a 200μL sterile pipette tip to scratch the surface of the monolayer cells, and wash the floating cells remaining in the well with PBS. Take pictures under a microscope to record the area of ​​the scratch area. Garcinone C (1μM) and resveratrol (1μM) were added to the drug treatment group, and human immortalized keratinocytes were cultured and treated with cell culture medium without fetal bovine serum for 24 hours. After the culture was completed, take pictures to record the area of ​​the scratch area for 24 hours.

[0079] The results are as follows Figure 5 As shown, the results showed that after UV irradiation, the healing ability of cell scratches was significantly reduced, while Garcinone C and resveratrol could promote the healing ability of cell scratches under UV irradiation, and the healing effect of Garcinone C was higher than that of the resveratrol positive drug control group.

[0080] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0081] The above-described embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the patent application. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present application, several variations and improvements can also be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art, on the basis of the technical solutions provided in the present application, through logical analysis, reasoning or limited experiments, are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the attached claims, and the specification can be used to interpret the content of the claims.

Claims

1. Application of Jiashengwo C in the preparation of products for skin anti-aging and / or promoting skin repair.

2. The use according to claim 1, characterized in that: The product also includes auxiliary materials.

3. The use according to claim 1, characterized in that: The administration of the product includes oral administration and / or topical administration.

4. The use according to claim 1, characterized in that: The product includes a cosmetic, a food or a medicine.

5. The use according to claim 4, characterized in that: The cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

6. The use according to claim 4, characterized in that: The food includes one or more of functional food, beverage, health product and nutritional supplement.

7. The use according to claim 4, characterized in that: The dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

8. The use according to claim 3, characterized in that: The external application includes local transdermal administration and / or systemic transdermal administration.

9. The use according to any one of claims 1 to 8, characterized in that: Skin anti-aging and / or skin repair promotion refers to activating the expression of SIRT1; and / or Skin anti-aging and / or skin repair promotion refers to inhibiting the activity of matrix metalloproteinases; and / or Skin anti-aging and / or skin repair promotion refers to promoting collagen expression; and / or Skin anti-aging and / or skin repair refers to promoting cellular healing.

10. The use according to claim 9, characterized in that: The matrix metalloproteinase is MMP1; the collagen is one or both of type I collagen and type III collagen.

Images